Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Celldex Therapeutics Trading Down 7.5 %
NASDAQ:CLDX traded down $2.79 on Thursday, reaching $34.53. The stock had a trading volume of 711,086 shares, compared to its average volume of 685,627. The company has a 50-day moving average of $27.66 and a 200 day moving average of $30.05. The stock has a market cap of $1.61 billion, a P/E ratio of -16.14 and a beta of 2.43. Celldex Therapeutics has a 12-month low of $19.85 and a 12-month high of $57.20.
Analysts Set New Price Targets
Several analysts recently issued reports on CLDX shares. HC Wainwright increased their price target on Celldex Therapeutics from $60.00 to $73.00 and gave the company a "buy" rating in a report on Friday, July 1st. SVB Leerink lowered their price target on Celldex Therapeutics from $68.00 to $64.00 and set an "outperform" rating for the company in a report on Tuesday.